David Budd Email and Phone Number

Led partnership activities for top US ophthalmology data research firm. Identify and partnership opportunities for the IRIS Registry, the largest repository of ophthalmological practice data in the world. Led engagements with research partners as well as the American Academy of Ophthalmology (AAO) to enhance industry research capabilities and offerings. Lead partnership strategy with research, data, and tech companies to expand Verana’s capabilities and business opportunities to grow revenue to meet year on year sales and revenue targets provided by the board of directors.Engaged with life sciences company commercial, medical affairs, clinical research, and health outcomes senior leadership to develop custom data approaches for research to drive diagnosis and treatment in areas of critical medical unmet need in critical areas of eye disease. Provided thought leadership to shape medical research transformation driven by novel approaches to information.

I brought my two decades of experience in the Pharmaceutical Health Outcomes, Market Access, and Medical Affairs spaces to help clients take real world evidence through to insights to support the development innovative medicines, and build strategies to provide access to the patients who need them.Led consulting and research teams to work with pharmaceutical commercial, market access, health outcomes, and medical affairs clients to translate real world evidence through to insights to support the development innovative medicines, and build strategies to provide access to the patients who need them. Collaborated with our clients' senior leaders to define key questions (launch sequencing, patient populations, outcomes for differentiation) and define bespoke solutions via real world evidence to develop support strategies. Key projects include mixed real-world and primary market research to inform launch strategy, deploying AI models for patient finding (identifying currently undiagnosed patients) at risk using multi-source global data, and using machine learning algorithms to train CRM protocols (e.g. SalesForce) to allow company to identify “next best physician” for sales calls via patient and practice data gathered. All projects require initial business issue definition, identification of optimal data sources to address real unmet needs, and development and execution of analysis information and turn evidence into insights through innovative approaches and platforms. Interactions with senior executives, including C-suite leaders require being able to communicate scientific and modelling details in a digestible way.

HEOR lead for HIV therapeutic area portfolio. Lead the strategy and execution of health economics and outcomes research to demonstrate the value of pipeline and inline products for HIV therapeutic areas. Delivered three AMCP dossiers supporting Genvoya, Odefsey, and Descovy product launches in space of six months. Develop year-on-year and multi-year plans to provide real world and health economics data to drive medical affairs and access teams to ensure appropriate and optimal access of Gilead medicines. Develop economic value story and AMCP dossier for launch of E/C/F/TAF, R/F/TAF, and F/TAF product portfolio. Led engagements with external thought leaders and communications of HEOR information internally and externally. Developed Gilead corporate response to Institute for Clinical and Economic Review (ICER).Key projects included developing decision analytic and discrete events models to identify at-risk populations for HIV to target ‘PrEP’ (pre-exposure prophylaxis) plans for public health officials. Published model demonstrated potential public health benefits of appropriate targeting and outreach. Developed Markov models of disease progression to frame opportunities and value messages for the US and EU markets. Built cross-data platform to join medical claims, outcomes, and patient electronic health records to create epidemiologic projections in US of HIV burden of disease for next 25 years for government affairs discussions with US Congressional task force on HIV. Created network meta analyses to include clinical trial comparisons for multiple HIV products for presentation to UK NICE (National Institute for Health and Clinical Evidence).

Lead HEOR and market access activities for specialty medicines portfolio in EU region. Drive evidence-based strategies for EU region market access. Design and execute strategy for delivery of real world data to highlight value propositions for Eliquis and Orencia. Managed two strategic alliances and co-programme development with Pfizer (Eliquis) and Gilead Sciences (Daklinza). Coordinate global, regional, and market (country) plans for market access for three therapeutic portfolios.Was the most decorated member of the HEOR team, including winner of three BMS President’s Awards for outstanding performance.

Therapeutic area leader of neuroscience and immunoscience portfolios. Led global health economics and outcomes work for Orencia (RA) across multiple indications, and Alzheimer's drug development, including value story creation and market access development. Led partnership with Critical Path Institute and PCORI to develop and validate quality measures in Alzheimer’s disease patient care.Led research and development of global health outcomes and health economics programmes. Created evidence-based strategies for global market access. Drove strategy from value creation through life cycle management for assets. Developed and implemented analyses supporting health technology assessments and executed functional plans. Led market access teams focused on development of strategy, value story creation, and market access platforms. Member of company Clinical Protocol Review Committee. Successfully drove efforts qualifying multiple biomarkers for Phase 3 trials before CHMP. Multiple peer-reviewed scientific and market access publications.

Responsible for managing team of real world data researchers supporting strategic marketing and access. Delivered insights into the unmet needs for pharmaceutical customers (patients, physicians, payers) for products in virology (HCV, HIV), anti-infectives, and metabolic diseases. Led analytics for in-licencing opportunities, including market assessment and revenue growth. Managed global development partnership between J&J and Bayer for Xarelto. Led development of disease and economic models to drive access and pricing strategy for VX950 (HCV), Phase I and Phase II development strategy for HIV franchise, and early strategy for golimumab and ustekinumab (rheumatoid arthritis, psoriasis, psoriatic arthritis). Defined markets and opportunities and mentor team of analysts to identify appropriate data, create and execute analytics, and package and present findings. Represented J&J at conferences and advisory boards and produce publications to disseminate critical, market-shaping discoveries.

Responsibilities include managing all phases of biostatistical research, including clinical research projects, market research, product research and development. Create, review, and submit statistical analysis plans; core team member in drafting and reviewing clinical protocols and submissions. Key contributor and signatory to FDA submissions, including 510 (k) submissions. Develop, review, and maintain internal clinical and statistical standard operating procedures. Create, review, and submit technical, clinical, and market research reports. Core team member, new product requirements documents (PRDs) and market requirements documents (MRDs)

Responsible for managing external customer engagements and support for 200 person consulting company. Identified, staffed, and managed regional teams of front-line sales and marketing representatives. Directly responsible to manage a team of applications engineers who provide support to world-wide customer base for a PC-based, semiconductor yield enhancement software product. Responsibilities included resource allocation; development of support and maintenance plans; management of overseas support representatives; development of sales and support collateral; development and deployment of training programs; strategies, and materials; creating and maintaining product installations; providing professional yield ramp consulting services, including data analysis, software customisation, and internal code development. Developed strategy and procedure for contract (statement of work) framework for sales and support of products.Key projects included developing bespoke data mining solutions for the largest foundries in Asia (TSMC, UMC) for root cause analysis of production failure. Created machine learning and proprietary scripting algorithms to automate data capture (SQL), analysis, and CAPA procedures for production. Created integrated, seamless database to tool automations for real-time monitoring and corrective action.

Responsible for all phases of statistical methodology, including experimental design, protocol drafting and review, analysis plan development, analysis, report preparation, and periodical submission for consulting company specialising in outcomes research and economic modelling in the pharmaceutical industry.

Researcher in HIV disease.Designed and carried out analyses for stratification of risk factors for the development and progression of HIV disease. Developed models for predicting who would progress from HIV positive status to AIDS and who would not.